VBI Vaccines, Inc. (NASDAQ:VBIV) major shareholder Opko Health, Inc. purchased 655,738 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was acquired at an average price of $3.05 per share, for a total transaction of $2,000,000.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of VBI Vaccines, Inc. (NASDAQ:VBIV) opened at $4.20 on Friday. The company has a quick ratio of 1.91, a current ratio of 2.00 and a debt-to-equity ratio of 0.18.

ILLEGAL ACTIVITY WARNING: “VBI Vaccines, Inc. (VBIV) Major Shareholder Purchases $2,000,000.90 in Stock” was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/vbi-vaccines-inc-vbiv-major-shareholder-purchases-2000000-90-in-stock/1677318.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. KCG Holdings Inc. bought a new position in VBI Vaccines in the 1st quarter valued at approximately $512,000. Goldman Sachs Group Inc. bought a new position in VBI Vaccines in the 1st quarter valued at approximately $383,000. Bank of Montreal Can raised its holdings in VBI Vaccines by 8.6% in the 2nd quarter. Bank of Montreal Can now owns 63,398 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 5,000 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new position in VBI Vaccines in the 2nd quarter valued at approximately $187,000. Finally, Bank of New York Mellon Corp bought a new position in VBI Vaccines in the 2nd quarter valued at approximately $193,000. Institutional investors own 31.50% of the company’s stock.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Saturday, July 15th. Canaccord Genuity assumed coverage on shares of VBI Vaccines in a research note on Wednesday. They set a “buy” rating and a $10.00 price objective on the stock. ValuEngine upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Noble Financial reiterated a “buy” rating on shares of VBI Vaccines in a research note on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. VBI Vaccines currently has a consensus rating of “Hold” and a consensus price target of $10.00.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.